The changing landscape of AML
The changing landscape of AML
Using bioinformatics and genomics to treat AML
Blinatumomab for relapsed/refractory Burkitt's lymphoma
MOR208 plus lenalidomide in r-r diffuse large B-cell lymphoma
Chemoimmunotherapy or BTK inhibition for patients with CLL
CLL14: A chemotherapy-free regimen of venetoclax plus obinutuzumab for CLL
Lymphodepleting chemotherapy in order to safely improve the expansion of HER2-CAR T cells in patients with advanced sarcomas
New developments in soft tissue and bone sarcoma research
Patient treatment preferences in relapsed/refractory multiple myeloma
The international myeloma working group frailty score for elderly patients with multiple myeloma
Osteoporosis and osteopenia in elderly patients
Treating myelodysplastic syndromes